Form 4: Sangamo Therapeutics VP, Head of Research, Amy Pooler, Reports Stock Transactions for Tax Obligations
SEC Form 4 Filing
Amy Pooler, VP, Head of Research at Sangamo Therapeutics, reports the disposition of shares to cover tax obligations related to RSU vesting.
Summary
- On May 24 and 25, 2024, Amy Pooler, VP, Head of Research at Sangamo Therapeutics, disposed of 702 and 493 shares of common stock, respectively, to cover mandatory tax withholding.
- These transactions were not discretionary trades but were required due to the vesting of RSU grants under the company's 2018 Equity Incentive Plan.
- The shares were surrendered at a price of $0.60 per share.
- Following these transactions, Pooler beneficially owns 195,119 shares of Sangamo Therapeutics common stock.
- These holdings include shares from RSU grants vesting through February 2026.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing stock transactions for tax purposes, indicating a neutral sentiment.
Future Outlook
The document does not contain any specific forward-looking statements regarding the company's future performance.
Industry Context
Form 4 filings are routine disclosures required by the SEC when company insiders, like officers and directors, trade their company's stock. This filing indicates transactions related to vested equity compensation.
Key Dates
| Date | Description |
|---|---|
| 05/24/2024 | Disposition of 702 shares for tax withholding. |
| 05/25/2024 | Disposition of 493 shares for tax withholding. |
| 05/29/2024 | Date of Form 4 signature. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.